CIELO: a randomized, double-blind, placebo-controlled, phase 3 basket study of satralizumab in patients with NMDAR- or LGI1-antibody encephalitis - Gelfand, JM; Abboud, H; Irani, SR; Nakajima, H; Piquet, A; Pittock, SJ; Yeh, EA; Overell, J; Rajan, S; El-Khairi, M; Lee, S-T (Wiley, 2022)